FNY Managed Accounts’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q2
Sell
-130
Closed -$35K 212
2017
Q1
$35K Buy
+130
New +$36.8K 0.11% 275
2016
Q2
Sell
-3,100
Closed -$807K 309
2016
Q1
$807K Buy
+3,100
New +$819K 1.41% 14
2014
Q2
Sell
-500
Closed -$153K 99
2014
Q1
$153K Buy
+500
New +$159K 0.41% 34

Other funds holding BIIB

FNY Managed Accounts's BIIB Position: Q2 2017 in Review

FNY Managed Accounts sold out of Biogen (BIIB) in Q2 2017, closing a stake of 130 shares — an estimated $35K sold.

FNY Managed Accounts first reported a position in BIIB in Q1 2014 and held it in 3 quarters. The position peaked at $807K in Q1 2016. 992 funds tracked by Wall St. Rank hold BIIB as of Q2 2017.

  • FNY Managed Accounts reported no remaining Biogen position as of Q2 2017 after selling out during the quarter.
  • FNY Managed Accounts sold 130 Biogen shares in Q2 2017, an estimated $35K.
  • FNY Managed Accounts first reported a position in Biogen in Q1 2014 and held it in 3 quarters.
  • FNY Managed Accounts's Biogen position peaked at $807K in Q1 2016.
  • 992 funds tracked by Wall St. Rank held Biogen as of Q2 2017.

Based on FNY Managed Accounts's 13F filing for Q2 2017, filed 10 Aug 2017.